Book Value per Share: xoma.com (XOMA)

XOMA Royalty (XOMA) is considered an authoritative player in the biopharmaceutical licensing space, building a resilient portfolio by financing early-stage drug development. The asset value tracked on this chart, which currently stands at 7.82, reflects the dynamics of a business that profits from royalty payments on successful drugs developed by third-party behemoths. This strategy allows the company to generate profit while avoiding the colossal expenditures associated with its own research.
Summary analytical data breakdowns for XOMA Corporation (XOMA)

The XOMA Royalty (XOMA) model, which monetizes intellectual property through royalties from drug sales, accumulates net assets without incurring operational production costs. This metric is calculated as the difference between total assets and liabilities divided by the number of shares, allowing for an assessment of an investor's actual stake based on the target book value per share.